For pharmaceutical companies and research institutions, the quality of raw materials directly impacts the success of drug development. NINGBO INNO PHARMCHEM CO.,LTD. emphasizes the importance of sourcing high-purity Erlosamide (CAS 175481-36-4) to ensure the efficacy and safety of final pharmaceutical products. Erlosamide, a key intermediate, is critical for therapies targeting neurological disorders and pain management.

The primary application of Erlosamide lies in its role as an anticonvulsant, particularly for treating partial-onset seizures. Its molecular structure and biochemical properties allow it to selectively enhance the slow inactivation of voltage-gated sodium channels. This targeted approach helps to stabilize overactive nerve cells, thereby preventing the uncontrolled electrical discharges that lead to seizures. For pharmaceutical manufacturers looking to buy this compound, understanding its purity level is paramount, as anything less than >98% can compromise the final drug's performance.

Beyond its established use in epilepsy, Erlosamide shows significant promise in the treatment of neuropathic pain, such as that associated with diabetes. This expanded therapeutic scope makes Erlosamide an increasingly valuable intermediate. When considering the purchase of Erlosamide, researchers and procurement specialists must partner with reliable suppliers like NINGBO INNO PHARMCHEM CO.,LTD. to guarantee product integrity and consistent availability. Competitive pricing also ensures that cutting-edge treatments become more accessible.

The availability of detailed technical specifications, including Erlosamide's exact CAS number (175481-36-4) and its white powder appearance, is a testament to the meticulous quality control measures in place. NINGBO INNO PHARMCHEM CO.,LTD. is committed to providing pharmaceutical-grade Erlosamide, supporting the vital work of developing new medicines that address unmet medical needs.